Forget Recursion Pharmaceuticals stock. This is a much better buy.

Eli Lilly is a safer way to capitalize on AI-driven drug discovery.

What’s Happening With RXRX Stock?

RXRX Stock jumps after JPMorgan upgrade and trial data boost, fueling investor optimism in Recursion’s AI drug discovery ...
Nasdaq

Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.

Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...
GEN

Recursion’s Ambitions: Developing 100+ Candidates, Joining with Exscientia

Chris Gibson, PhD, Recursion’s co-founder and CEO, discusses exclusively with GEN Edge his company’s ambitious plans to develop 100 pipeline candidates in roughly a decade, the savings in money and ...
Ars Technica

Recursion or while loops: Which is better?

This Q&A is part of a weekly series of posts highlighting common questions encountered by technophiles and answered by users at Stack Exchange, a free, community-powered network of 100+ Q&A sites.
Nasdaq

Recursion (RXRX) to Report Q2 Earnings: What's in the Cards?

We believe that Recursion RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is likely to beat expectations when it reports second-quarter 2024 results. The ...

Recursion Pharmaceuticals Stock Is Soaring Today: Here's Why

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight ...
NPR

Blake Crouch's New Novel, 'Recursion,' Is A Thriller With A Dash Of Sci-Fi

Blake Crouch's new novel, Recursion, is a thriller with a dash of sci-fi. It makes the case that we are the sum of our memories and asks what happens when our memories fail us. The novelist Blake ...